文献速递类风湿关节炎

转化生物标志物与关节组织离体模型作为类风湿关节炎药物开发工具

Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2018-07-24

本研究在OSKIRA-1三期临床研究的450份血清样本及骨、软骨、滑膜培养模型中检测骨、软骨及间质基质转换生物标志物,评估福坦替尼活性代谢物R406的抑制效果,发现该药在血清和骨/软骨培养中抑制CTX-I和C2M,但对C1M和C3M无临床或临床前效应,提示转化生物标志物可能有助于类风湿关节炎药物开发早期决策。

要点

  • 在OSKIRA-1血清和骨/软骨培养中,福坦替尼抑制CTX-I和C2M水平。
  • 在OSKIRA-1血清和滑膜培养中,福坦替尼对C1M和C3M无临床或临床前效应。
  • 转化生物标志物可能是类风湿关节炎药物开发早期评估与决策的潜在工具。

核心结论

  • 这些数据表明转化生物标志物是类风湿关节炎治疗药物开发中早期评估和决策的潜在工具。

研究设计与样本

  • 研究在OSKIRA-1(一项福坦替尼治疗类风湿关节炎疗效的三期临床研究)的450份血清样本中,于基线和随访时检测骨、软骨和间质基质转换生物标志物(CTX-I、C1M、C2M、C3M)。
  • 随后在骨oclast、软骨和滑膜膜培养物与福坦替尼活性代谢物R406共培养的条件培养基中检测相同生物标志物,以评估药物诱导的抑制水平。

主要发现

  • 在OSKIRA-1血清样本以及骨oclast和软骨培养中,福坦替尼抑制了CTX-I和C2M水平。
  • 在OSKIRA-1血清样本和滑膜膜培养中,福坦替尼对C1M或C3M均未介导任何临床或临床前效应,而此前这些标志物与疾病反应和疗效相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic and degenerative autoimmune joint disease that leads to disability, reduced quality of life, and increased mortality. Although several synthetic and biologic disease-modifying antirheumatic drugs are available, there is still a medical need for novel drugs that control disease progression. As only 10% of experimental drug candidates for treatment of RA that enter phase I trials are eventually registered by the Food and Drug Administration, there is an immediate need for translational tools to facilitate early decision-making in drug development. In this study, we aimed to determine if the inability of fostamatinib (a small molecule inhibitor of Syk) to demonstrate sufficient efficacy in phase III of a previous clinical study could have been predicted earlier in the development process. METHODS: Biomarkers of bone, cartilage, and interstitial matrix turnover (C-telopeptide of type I collagen [CTX-I], matrix metalloproteinase-derived types I, II, and III collagen neoepitopes [C1M, C2M, and C3M]) were measured in 450 serum samples from the Oral Syk Inhibition in Rheumatoid Arthritis 1 study (OSKIRA-1, a phase III clinical study of the efficacy of fostamatinib in RA) at baseline and follow-up. Additionally, the same biomarkers were subsequently measured in conditioned media from osteoclast, cartilage, and synovial membrane cultured with the active metabolite of fostamatinib, R406, to assess the level of suppression induced by the drug. RESULTS: In OSKIRA-1 serum samples and osteoclast and cartilage cultures, fostamatinib suppressed the levels of CTX-I and C2M. In OSKIRA-1 serum samples and synovial membrane cultures, fostamatinib did not mediate any clinical or preclinical effect on either C1M or C3M, which have previously been associated with disease response and efficacy. CONCLUSION: These data demonstrate that translational biomarkers are a potential tool for early assessment and decision-making in drug development for RA treatment.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kjelgaard-Petersen CF, Platt A, Braddock M, et al. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis Rheumatol. 2018. PMID: 29669391. doi:10.1002/art.40527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。